The goal of this clinical trial is to learn about the effects of transcranial direct current stimulation (tDCS) combined with aerobic exercise in non-specific low back pain patients. The main question aims to answer: • Which are the effects of tDCS treatment combined with aerobic exercise compared to Sham tDCS combined with aerobic exercise in non-specific Low Back Pain? Participants will be asked to complete questionnaires and they will receive treatments as tDCS or Sham tDCS and aerobic exercise (treadmill walking). Researchers will compare a group who is treated with a combination of tDCS and aerobic exercise versus a group receiving placebo tDCS and aerobic exercise to see the effects on pain intensity, pressure pain, disability, kinesiophobia, quality of life, catastrophism, Heart Rate Variability and cortical excitation.
Low back pain (LBP) is the main cause of disability worldwide with a prevalence of 70 to 85% of the population. Chronic LBP (CLBP) is defined as a pain lasting more than 12 weeks. CLBP does not have peripheral nociceptive stimuli, but it is characterized by the presence of a chronic change in neuroplasticity. Transcranial direct current stimulation (tDCS) is a type of therapeutic intervention that can modulate the cortical excitability of a wide neural network involved in the elaboration of pain, resulting in an efficacy option for CLBP treatment. Aerobic exercise represents another typology of effective therapeutic intervention in the treatment of pain intensity and disability related to CLBP. The main objective of the study is to determine the efficacy of tDCS combined with aerobic exercise compared to shame/placebo tDCS combined with aerobic exercise in middle-aged subjects with non-specific CLBP in the short, medium and long term. Methods: In a double-blinded pilot randomized controlled trial, 38 subjects aged between 18 and 65 years, with a diagnose of non-specific LBP for 3 months, a Visual Analogue Scale (VAS) result of \>20mm and a Roland-Morris Scale result of \>4 will be selected for the following study. Participants will be divided in two groups of 19 subjects each one: experimental group A (20 minutes of tDCS at 2 mili Amper + 20-30 minutes of aerobic exercise at 60-80% of HRmax) and controlled group B (30 seconds of sham/placebo tDCS at 2milli amperes + 20-30 minutes of aerobic exercise at 60-80% of maximum heart rate). The following outcomes will be measured: pain intensity (100mm VAS), pressure pain (pressure algometer), disability (Roland-Morris questionnaire), kinesiophobia (Tampa Scale for kinesiophobia), quality of life (SF-12 health questionnaire), catastrophism (Pain Catastrophizing Scale), Heart Rate Variability ( Polar Team) and cortical excitation (Critical Flicker Fusion).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
38
Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with therapeutic parameters
Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with sham tDCS
Eurpean University of Madrid
Villaviciosa de Odón, Madrid, Spain
RECRUITINGHospital Universitario Fundación Alcorcón
Alcorcón, Spain
RECRUITINGPain intensity
Measured with Visual Analogue Scale of 100 mm
Time frame: At baseline
Pain intensity
Measured with Visual Analogue Scale of 100 mm
Time frame: At the first month after intervention onset (after completion of the 12 treatment sessions).
Pain intensity
Measured with Visual Analogue Scale of 100 mm
Time frame: Follow-up at the third month after treatment completion
Pain intensity
Measured with Visual Analogue Scale of 100 mm
Time frame: Follow-up at the sixth month after treatment completion
Pressure pain
Measured with a pressure algometer
Time frame: At baseline
Pressure pain
Measured with a pressure algometer
Time frame: At the first month after intervention onset (after completion of the 12 treatment sessions).
Pressure pain
Measured with a pressure algometer
Time frame: Follow-up at the third month after treatment completion
Pressure pain
Measured with a pressure algometer
Time frame: Follow-up at the sixth month after treatment completion
Disability
Measured with Roland-Morris scale Spanish version, minimum and maximum values go from 0 (absence of disability) until 24 (maximum disability)
Time frame: At baseline
Disability
Measured with Roland-Morris scale Spanish version, minimum and maximum values go from 0 (absence of disability) until 24 (maximum disability)
Time frame: At the first month after intervention onset (after completion of the 12 treatment sessions).
Disability
Measured with Roland-Morris scale Spanish version, minimum and maximum values go from 0 (absence of disability) until 24 (maximum disability)
Time frame: Follow-up at the third month after treatment completion
Disability
Measured with Roland-Morris scale Spanish version, minimum and maximum values go from 0 (absence of disability) until 24 (maximum disability)
Time frame: Follow-up at the sixth month after treatment completion
Kinesiophobia
Measured with Tampa Kinesiophobia Scale questionnaire (TSK-11SV) Spanish version. Minimum and maximum values are between 11 and 44 point, a result with higher values indicates higher level of kinesiofobia.
Time frame: At baseline
Kinesiophobia
Measured with Tampa Kinesiophobia Scale questionnaire (TSK-11SV) Spanish version. Minimum and maximum values are between 11 and 44 point, a result with higher values indicates higher level of kinesiofobia.
Time frame: At the first month after intervention onset (after completion of the 12 treatment sessions)
Kinesiophobia
Measured with Tampa Kinesiophobia Scale questionnaire (TSK-11SV) Spanish version. Minimum and maximum values are between 11 and 44 point, a result with higher values indicates higher level of kinesiofobia.
Time frame: Follow-up at the third month after treatment completion
Kinesiophobia
Measured with Tampa Kinesiophobia Scale questionnaire (TSK-11SV) Spanish version. Minimum and maximum values are between 11 and 44 point, a result with higher values indicates higher level of kinesiofobia.
Time frame: Follow-up at the sixth month after treatment completion
Quality of life questionnaire
Measured with SF-12 Health Questionnaire Spanish version. A zero score indicates the lowest level of dimension measured by the scale, and 100 indicates the highest level of the measured dimension
Time frame: Al baseline
Quality of life questionnaire
Measured with SF-12 Health Questionnaire Spanish version. A zero score indicates the lowest level of dimension measured by the scale, and 100 indicates the highest level of the measured dimension
Time frame: At the first month after intervention onset (after completion of the 12 treatment sessions)
Quality of life questionnaire
Measured with SF-12 Health Questionnaire Spanish version. A zero score indicates the lowest level of dimension measured by the scale, and 100 indicates the highest level of the measured dimension
Time frame: Follow-up at the third month after treatment completion
Quality of life questionnaire
Measured with SF-12 Health Questionnaire Spanish version. A zero score indicates the lowest level of dimension measured by the scale, and 100 indicates the highest level of the measured dimension
Time frame: Follow-up at the sixth month after treatment completion
Catastrophism
Measured with Pain Catastrophism Scale Spanish version. The total score ranges from 0 to 52. Higher scores reflect higher levels of catastrophic thinking.
Time frame: At baseline
Catastrophism
Measured with Pain Catastrophism Scale Spanish version. The total score ranges from 0 to 52. Higher scores reflect higher levels of catastrophic thinking.
Time frame: At the first month after intervention onset (after completion of the 12 treatment sessions)
Catastrophism
Measured with Pain Catastrophism Scale Spanish version. The total score ranges from 0 to 52. Higher scores reflect higher levels of catastrophic thinking.
Time frame: Follow-up at the third month after treatment completion
Catastrophism
Measured with Pain Catastrophism Scale Spanish version. The total score ranges from 0 to 52. Higher scores reflect higher levels of catastrophic thinking.
Time frame: Follow-up at the sixth month after treatment completion
Cortical excitation
Measured with Critical Flicker Fusion Threshold
Time frame: At baseline
Cortical excitation
Measured with Critical Flicker Fusion Threshold
Time frame: At the first month after intervention onset (after completion of the 12 treatment sessions)
Cortical excitation
Measured with Critical Flicker Fusion Threshold
Time frame: Follow-up at the third month after treatment completion
Cortical excitation
Measured with Critical Flicker Fusion Threshold
Time frame: Follow-up at the sixth month after treatment completion
Heart Rate Variability
Measured with Polar Heart Rate belt
Time frame: At baseline
Heart Rate Variability
Measured with Polar Heart Rate belt
Time frame: At the first month after intervention onset (after completion of the 12 treatment sessions)
Heart Rate Variability
Measured with Polar Heart Rate belt
Time frame: Follow-up at the third month after treatment completion
Heart Rate Variability
Measured with Polar Heart Rate belt
Time frame: Follow-up at the sixth month after treatment completion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.